MedTrace Logo

Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer

NCT00515866 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2013-12-20

No results posted yet for this study

Summary

The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with gemcitabine chemotherapy for the treatment of pancreatic cancer.

Conditions

  • Pancreatic Neoplasms

Interventions

DRUG

KU-0059436 (AZD2281)(PARP inhibitor)

oral

DRUG

Gemcitabine

intravenous injection

Sponsors & Collaborators

Principal Investigators

  • Howard A Burris III, MD · The Sarah Cannon Cancer Center

  • Jane Robertson, BSc, MBCHB, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2011-10-31
Completion
2012-07-31

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00515866 on ClinicalTrials.gov